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Improving Adjuvant Endocrine Treatment
Tailoring in Premenopausal Women With
Hormone Receptor–Positive Breast Cancer
Matteo Lambertini, MD, PhD1,2; Eva Blondeaux, MD1; Francesco Perrone, MD3; and Lucia Del Mastro, MD1,2
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical
context. A case presentation is followed by a description of diagnostic and management challenges, a review of
the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this
series is to help readers better understand how to apply the results of key studies, including those published in
Journal of Clinical Oncology, to patients seen in their own clinical practice.
INTRODUCTION
The Oncology Grand Rounds series is designed to
place original reports published in the Journal of
Clinical Oncology into clinical context. A case pre-
sentation is followed by a description of diagnostic and
management challenges, a review of the relevant lit-
erature, and a summary of the authors’ suggested
management approaches. The goal of this series is
to help readers better understand how to apply the
results of key studies, including those published in
JCO, to patients seen in their own clinical practice.
CASE PRESENTATIONS
A 41-year-old premenopausal woman was diagnosed
with stage I breast cancer; she underwent lumpectomy
and sentinel lymph node dissection for a left-sided
breast cancer measuring 1.1 cm. None of the two
sentinel lymph nodes contained metastatic carci-
noma. The tumor had ductal histology and was con-
sidered grade 1 of 3. Immunohistochemical studies
showed that the tumor was strongly positive for es-
trogen and progesterone receptor expression, was
negative for human epidermal growth factor receptor 2
(HER2) overexpression, and had a Ki-67 score of 11%.
A 39-year-old premenopausal woman was diagnosed
with stage I breast cancer; she underwent mastectomy
and sentinel lymph node dissection for a right-sided
breast cancer measuring 1.1 cm. The sentinel lymph
node did not contain metastatic carcinoma. The tumor
had ductal histology and was considered grade 2 of 3.
Immunohistochemical analysis showed HER2-negative
disease with intermediate positivity for estrogen and
progesterone receptor expression. A 21-gene assay was
requested and returned a recurrence score (RS) of 21.
A 40-year-old premenopausal woman presented with
stage II breast cancer; she underwent quadrantectomy
and sentinel lymph node dissection for a left-sided
breast cancer measuring 1.1 cm. One of three sentinel
lymph nodes contained metastatic carcinoma. The
tumor had ductal histology and was considered grade
2 of 3. Immunohistochemical studies showed HER2-
negative disease with intermediate positivity for es-
trogen and progesterone receptor expression. At
another institution, adjuvant chemotherapy followed
by radiation therapy (without axillary dissection) and
endocrine therapy was recommended. After four cy-
cles of adjuvant docetaxel and cyclophosphamide, she
developed chemotherapy-induced amenorrhea; nev-
ertheless, a blood test 1 month after chemotherapy
completion showed estradiol and follicle-stimulating
hormone (FSH) levels in the premenopausal range.
She came to our attention seeking a second opinion to
discuss the optimal adjuvant endocrine treatment.
A 39-year-old premenopausal woman was diagnosed
with stage II breast cancer; she underwent mastec-
tomy and axillary node dissection for a right-sided
breast cancer measuring 2.3 cm. Three of twelve
axillary nodes contained metastatic carcinoma. The
tumor had ductal histology and was considered grade
3 of 3. Immunohistochemical analysis showed HER2-
negative disease with high (95%) and intermediate
(40%) positivity for estrogen and progesterone re-
ceptor expression, respectively.
All four clinical cases were discussed at our weekly
multidisciplinary tumor board.
CHALLENGES IN DIAGNOSIS AND MANAGEMENT
Breast cancer is the most common malignancy in
premenopausal women,1 accounting for more than
50% of all new occurrences in some countries.2 De-
spite higher chances of developing aggressive breast
cancer subtypes, the majority of tumors in pre-
menopausal patients have positive estrogen and
progesterone receptor expression.3 Therefore, endo-
crine treatment is a mainstay adjuvant therapy for
these patients. Optimal and refined estimation of
prognosis and treatment benefit are key factors for
choosing the best adjuvant treatment, which includes
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the possibility of adding chemotherapy in women with
hormone receptor–positive tumors.4 This is of particular
relevance for premenopausal patients, given the significant
chemotherapy-related risk of long-term adverse effects with
major impact on quality of life.5 These potential age-related
negative consequences of chemotherapy include impair-
ment of fertility and chances of futuremotherhood, which are
highly relevant concerns that influence patient choices and
adherence toward the recommended treatments and sub-
sequently their disease-related outcomes.6-8
Age andmenopausal status are crucial factors in the choice
of the optimal adjuvant treatment.4 Recent data suggest
that the known independent poor prognostic value of young
age at diagnosis is restricted to hormone receptor–positive
tumors.9-11 There are possible clinical and biologic expla-
nations for these findings. First, these studies were con-
ducted when tamoxifen alone was considered the standard
of care as adjuvant endocrine treatment.12 Therefore,
a significant proportion of premenopausal patients were
undertreated according to current recommendations.13 Sec-
ond, young age is associated with suboptimal adherence to
adjuvant endocrine treatment.14,15 Fertility and pregnancy-
related concerns represents key factors for noninitiation and
early treatment discontinuation.16,17 Finally, there are potential
biologic differences between breast cancers arising in young
and older patients,18,19 particularly for hormone receptor–
positive tumors.20 These data further highlight that specific
attention should be paid to the management—including se-
lection of the best adjuvant endocrine treatment—of hormone
receptor–positive breast cancer in premenopausal women.
For many years, tamoxifen has been the standard adjuvant
endocrine treatment option for premenopausal women with
hormone receptor–positive tumors.12 In recent years, evi-
dence on the role of ovarian function suppression (OFS)
added to tamoxifen or to an aromatase inhibitor (AI) has
radically changed the endocrine treatment landscape in
this setting.13 Although a better understanding about how to
integrate genomic information with classic clinicopatho-
logic features has significantly improved our ability to es-
timate patient prognosis and chemotherapy benefit,21,22
adjuvant endocrine treatment tailoring in premenopausal
women remains challenging.23,24 Therefore, having a new
tool that could aid and engage patients and physicians
during endocrine treatment decision making represents an
important resource with a crucial impact on daily clinical
practice.
SUMMARY OF THE RELEVANT LITERATURE
Evolving Adjuvant Endocrine Treatment Landscape in
Premenopausal Women
The use of tamoxifen for 5 years significantly reduces the
risk of breast cancer recurrence and death during the first
15 years after diagnosis in all patients with hormone
receptor–positive tumors, irrespective of age at diagnosis.25
In premenopausal patients with hormone receptor–positive
breast cancer, the development of chemotherapy-induced
amenorrhea is associated with improved prognosis.26,27
Nevertheless, the benefit of temporary (ie, using a gonad-
otropin-releasing hormone agonist [GnRHa]) or permanent
(ie bilateral oophorectomy or ovarian irradiation) OFS in
addition to tamoxifen has remained unclear until recently.28
Three trials have now clarified the role of escalating ad-
juvant endocrine treatment by combining OFS with ta-
moxifen (Table 1).29-31 The E-3193 INT-0142 study did not
show any difference in disease-free survival (DFS) or overall
survival (OS) between patients treated with tamoxifen alone
or combined with OFS for 5 years.29 Notably, this was
a small trial that included low-risk patients (primary tumors
# 3 cm, node-negative disease, no prior adjuvant che-
motherapy allowed). Conversely, a significant DFS and OS
improvement was observed by adding OFS to tamoxifen in
the updated analysis of SOFT and in the ASTRRA study.30,31
SOFT was a three-arm trial in which premenopausal pa-
tients were randomly allocated to receive tamoxifen alone
or combined with OFS or the combination of OFS plus
exemestane.32 OFS was administered for 5 years; patients
with or without exposure to prior chemotherapy were included,
but those who received cytotoxic therapy (53% of the study
population) could be randomly assigned within 8months after
its completion only in the presence of premenopausal estradiol
levels (and during this period, patients were allowed to receive
tamoxifen alone). The survival benefits observed for the pri-
mary comparison (tamoxifen plusOFS v tamoxifen alone) were
more evident in patients with prior exposure to chemotherapy
and in women younger than age 35 years.30 In the ASTRRA
trial, OFS was administered for 2 years; only patients who
received prior chemotherapy were eligible if they remained
premenopausal or resumed ovarian function (defined by
menstrual history or FSH levels) within 2 years after its
completion.33
By providing the most profound suppression of hormone
serum levels,34,35 the combination of OFS plus an AI repre-
sents another step in escalating adjuvant endocrine treat-
ment. Three trials assessed this combination (Table 2).30,36,37
With a two-by-two factorial design, the ABCSG-12 study
randomly allocated patients to receive OFS plus anastrozole or
tamoxifen with or without zoledronic acid. Patients who re-
ceived OFS plus anastrozole had similar DFS but worse OS
compared with those who received OFS plus tamoxifen.36
Notably, adjuvant endocrine treatment was administered for
3 years, half of the study population also received adjuvant
bisphosphonates, and low-risk patients were included (75%
with primary tumors # 2 cm, 66% with node-negative dis-
ease, and only 5% with prior exposure to neoadjuvant che-
motherapy [adjuvant cytotoxic therapy was not allowed]).38
TEXT randomly allocated premenopausal patients with hor-
mone receptor–positive tumors to 5 years of OFS plus ta-
moxifen or exemestane.39 As in SOFT, patients were allowed
to receive prior chemotherapy but, when administered (60%
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of the study population), OFS had to be started concomitantly
with cytotoxic therapy. Patients not receiving chemotherapy
started oral endocrine therapy 6-8 weeks after GnRHa initi-
ation. In the joint analysis of TEXT and SOFT, OFS plus
exemestane was superior in terms of DFS to OFS plus ta-
moxifen without difference in OS.30 The HOBOE trial was
a three-arm study that randomly allocated premenopausal
patients with hormone receptor–positive tumors to 5 years of
OFS plus tamoxifen or letrozole or letrozole plus zoledronic
acid.37 The majority of patients (63%) received prior che-
motherapy. The DFS benefit observed with OFS plus letrozole
over tamoxifen was clinically meaningful but reached sta-
tistical significance only when combined with adjuvant
bisphosphonates. No difference in OS was observed.37
On the basis of these data, current guidelines recommend
the use of tamoxifen alone for women with low-risk of
disease recurrence. For all other patients, particularly those
deemed at sufficient risk to justify chemotherapy use, OFS
should be considered but without clear preference and
guidance on when to combine it with tamoxifen or an
AI.4,13,40-42
Considering the impact of the toxicity profiles of the different
treatments on the patients’ quality of life, the available
options should be clearly discussed with all women and
may influence the final choice (Table 3).29,43,44 Notably, up
to 20%-25% of patients in the different trials opted for early
cessation of endocrine treatment, with higher risk of non-
adherence noted in women younger than age 35 years.45
Hence, continuous monitoring of adverse events and
compliance is crucial; switching to a different option when
the ongoing therapy is not tolerated should be preferred
over treatment cessation.
When counseling patients on the risk/benefit ratio of the
proposed adjuvant treatments, together with the toxicity
profile, it is crucial to provide precise information of indi-
vidual prognosis and expected benefit of the proposed
therapies. For premenopausal women with hormone
receptor–positive/HER2-negative tumors, refining these
estimations would be crucial not only to decide about
chemotherapy use but also to distinguish between the
different available adjuvant endocrine treatment options.
Refining Prognostication of Patients With Hormone
Receptor–Positive/HER2-Negative Breast Cancer
Indication for adjuvant chemotherapy before endocrine
treatment in patients with hormone receptor–positive/
HER2-negative tumors represents one of the most chal-
lenging decisions in the breast cancer field. This is even
more complex in premenopausal women because of the
additional potential age-related negative consequences of
chemotherapy.
In premenopausal patients with hormone receptor–
positive/HER2-negative breast cancer without nodal in-
volvement, a secondary analysis of TAILORx has recently
provided important guidance on estimating chemotherapy
benefit using the 21-gene assay.22 Although no chemo-
therapy benefit is expected with an RS of 0-15, some
benefit was observed in women age 50 years or younger
with an RS of 16-25.46 This benefit was mostly evident in
premenopausal women older than age 45 years, sug-
gesting a potential endocrine effect of chemotherapy
mediated by the development of premature ovarian in-
sufficiency, an adverse effect happening more frequently
among older premenopausal women.22 Additional dis-
section of the TAILORx cohort of women age 50 years and
younger with an RS of 16 to 25 according to their clinical
risk (defined by tumor size and histologic grade) showed
a significant chemotherapy benefit in patients with an RS of
21-25 irrespective of their clinical risk (estimated absolute
gain in distant recurrence at 9 years between 6.4% and
8.7%) as well as in those with an RS of 16-20 and high
clinical risk (estimated absolute gain in distant recurrence
at 9 years of 6.5%). Importantly, most of premenopausal
patients received tamoxifen alone as adjuvant endocrine
treatment; the absolute benefit observed with chemo-
therapy in TAILORx appears comparable to the one ex-
pected with OFS plus AI compared with tamoxifen alone in
TEXT and SOFT. In patients with an RS of 16-20 and low
clinical risk, no chemotherapy benefit was observed (es-
timated absolute gain in distant recurrence at 9 years of
20.2%).22
Despite providing robust prognostic information and predic-
tion of chemotherapy benefit in patients with node-negative
TABLE 3. Main Results of the Patient-Reported Outcomes With the Different Available Adjuvant Endocrine Treatment Options for Premenopausal Patients
OFS 1 Tam (v Tam alone) OFS 1 AI (v OFS 1 Tam)
↓ health-related QoL  health-related QoL
↑ endocrine symptoms (hot flushes, sweats, sleep disturbance) ↓ hot flushes and sweats
↓ sexual functioning (vaginal dryness, difficulties in becoming
aroused, decline in sexual interest)
↓ sexual functioning (vaginal dryness, difficulties in becoming
aroused, decline in sexual interest)
↓ bone and joint pain ↑ bone and joint pain
↓ coping effort
↑ treatment burden
Abbreviations: AI, aromatase inhibitor; OFS, ovarian function suppression; QoL, quality of life; Tam, tamoxifen.
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hormone receptor–positive/HER2-negative breast cancer,
genomic tests have not been developed to select the
most appropriate adjuvant endocrine treatment. The study
by Pagani et al,47 which accompanies this article, provides
important data to guide and improve adjuvant endocrine
treatment tailoring in premenopausal women with hor-
mone receptor–positive/HER2-negative tumors. A secondary
analysis of SOFT and TEXT was conducted to refine the
estimates of the absolute magnitude of endocrine treatment
effects in preventing distant recurrences according to patient
prognosis. Classic clinicopathologic features (ie, age, tumor
size, nodal status, grade, estrogen receptor level, pro-
gesterone receptor level, and Ki-67 expression level) were
combined into a single continuous value named composite
risk (ie, Regan risk score). Using the STEPP methodology,
absolute treatment effects were investigated across the
continuum of composite risk for 4,891 premenopausal
women with hormone receptor–positive/HER2-negative
breast cancer. The median follow-up was 9 years in TEXT
and was 8 years in SOFT. The main messages from this
analysis are the following: (1) in high-risk patients after
chemotherapy, the higher the risk of recurrence, the larger
the benefit expected with OFS plus exemestane compared
with OFS plus tamoxifen or tamoxifen alone (estimated
absolute gain in distant recurrence at 8 years up to 15%); (2)
in low-risk patients without prior chemotherapy (overall
8-year freedom from distant recurrence ranging between
97% and 99%), there were no clinically relevant differences
between the three endocrine treatment options (estimated
absolute gain in distant recurrence at 8 years with OFS of
approximately 1%); (3) in intermediate-risk patients, the
benefit of OFS plus exemestane compared with OFS plus
tamoxifen wasmore evident in the cohort of patients who did
not receive chemotherapy (estimated absolute gain in distant
recurrence at 8 years of up to 4%). Notably, selection of
adjuvant chemotherapy in SOFT and TEXT was based on the
same classic clinicopathologic features included in the
Regan risk score (at that time, genomic tests were not widely
available). On the basis of these data, together with the
recent secondary analysis of TAILORx, clinicians now
have valid tools to individualize and tailor the counseling of
premenopausal women with hormone receptor–positive/
HER2-negative breast cancer on the risk/benefit ratio of the
proposed adjuvant treatments (Fig 1). Results of the
RxPONDER trial (ClinicalTrials.gov identifier: NCT01272037)
investigating the benefit of adding chemotherapy to different
endocrine treatments in patients with one to three positive
nodes and an RS of 25 or lower are awaited to further refine
the counseling of the intermediate-risk population.
Practical Issues and Unanswered Questions
When the recent evidence on adjuvant endocrine treatment
in premenopausal women is translated into clinical care,
some practical issues and unanswered questions arise.
In premenopausal women receiving an AI as oral endocrine
therapy, complete OFS must be obtained (although this is
not required for tamoxifen). Combining a GnRHa with an AI
is associated with more profound OFS than a GnRHa plus
tamoxifen.34,35 However, incomplete OFS is expected in
approximately 20% of the patients receiving a GnRHa plus
AI.35 No prior exposure to chemotherapy, very young age,
and high body mass index are potential risk factors for
incomplete OFS to be considered during treatment de-
cision making.35,48 For the same reason, a GnRHa plus an
AI is not the preferred choice for patients with compliance
issues at risk for nonadherence to monthly injections.
Importantly, when a GnRHa plus an AI is chosen, a con-
tinuous monitoring of treatment adherence and the pos-
sible occurrence of physiologic changes that suggest
potential recovery of ovarian function (eg, cyclical fluctu-
ation of climacteric symptoms and menstrual resumption)
are crucial. Estradiol and FSH monitoring during treatment
can be considered.40,42,49 In the case of incomplete OFS
during treatment with a GnRHa plus an AI, switching to
tamoxifen (or bilateral oophorectomy) should be consid-
ered. The use of GnRH antagonists may partly overcome
concerns about inadequate OFS50; future studies are
awaited to define the role of GnRH antagonists in the
adjuvant endocrine treatment of premenopausal patients.
The need to obtain complete OFS in patients receiving
a GnRHa plus an AI may also impact the timing to start
pharmacologic OFS and oral endocrine therapy. When
chemotherapy is administered, concurrent administration of
a GnRHa is safe51,52 and is an effective strategy to reduce the
risk of premature ovarian insufficiency.52,53 This approach is
endorsed by current guidelines.4,40,42,54,55 Starting OFS be-
fore chemotherapy and continuing the treatment up to
5 years would also facilitate the choice of the oral endocrine
therapy partner. If OFS is not given concurrently and
chemotherapy-induced amenorrhea occurs, ovarian func-
tion should be constantly monitored, because it can resume
even beyond 2 years after chemotherapy completion56,57; an
AI alone in this setting should be avoided because of the
significant risk of ovarian function recovery.58
Among the potential long-term negative consequences of
OFS, especially when given concomitantly with an AI, par-
ticular attention should be given to bone loss. By reducing
risk of skeletal complications and potentially improving
survival outcomes,36-38,59 prophylactic use of bisphospho-
nates can be considered in patients with treatment-related
bone loss.42,60,61
Because of the significant risk of recurrence beyond 5 years
after diagnosis,62 extended adjuvant endocrine treatment is
the standard of care for many patients with hormone
receptor–positive breast cancer.63 Premenopausal women
have a higher risk of developing late recurrences62 and
appear to derive the greater benefit from extended adjuvant
endocrine treatment.64 Tamoxifen alone may be consid-
ered in women who remain premenopausal after the first
5 years of therapy, and an AI alone may be considered in
those who become postmenopausal.63 However, no
6 © 2019 by American Society of Clinical Oncology
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evidence exists to decide the optimal approach for
extending treatment in patients receiving OFS in the first
5 years.65
More evidence is needed to define the optimal adju-
vant endocrine treatment of premenopausal (and
postmenopausal) patients with hormone receptor–
positive/HER2-positive breast cancer.66-68 Subgroup
analysis of the SOFT, TEXT, and HOBOE trials showed
heterogeneity of treatment effect according to HER2
status and noted an apparent greater benefit from the
addition of OFS and a lesser efficacy of AIs in patients
with HER2-positive disease.30,37 However, no strong
conclusions can be derived because of the limited
number of patients included who had HER2-positive
disease and the lack of trastuzumab use for many of
them. The Regan risk score did not include patients with
HER2-positive disease.47
SUGGESTED APPROACHES TO MANAGEMENT
Several risk prediction models based on traditional clini-
copathologic features have been developed to refine dis-
ease prognostication for patients and aid in treatment
decision making.69 However, the performance of these
models in some patient subgroups, including pre-
menopausal women, has been shown to be suboptimal.69,70
In addition, the adjuvant endocrine treatment landscape for
premenopausal women has been revolutionized so that
reliable predictions about the expected benefit from adjuvant
therapies in these patients have become difficult. By im-
proving the stratification of patients’ prognosis and the
Regan risk score 
Intermediate risk†Low risk* High risk‡
Unclear CT
indications
No CT No CT CT CT 
21-gene assay§
RS 0-15
RS 16-20 low risk||
RS 16-20 high risk||
RS 21-25
RS 26-100
No CT No CT CT CT 
OFS + AI
OFS + Tam
Tam OFS + AI
OFS + AI
OFS + Tam
OFS + AI
OFS + Tam
OFS + AI Tam OFS + AI
Extended adjuvant endocrine treatment to be considered 
FIG 1. Proposed algorithm for the adjuvant treatment of premenopausal women with hormone receptor–positive/HER2-negative breast
cancer, integrating the results obtained with the Regan risk score and the 21-gene assay for the intermediate-risk group. (*) Example of
clinical case 1 (age 41 years; grade 1; pT1c pN0; estrogen receptor [ER]$ 50%; progesterone receptor [PR]$ 50%; Ki-67, 11%). (†)
Examples of clinical case 2 (age 39 years; grade 2; pT1c pN0; ER approximately 50%; PR approximately 50%; RS of 21) and clinical case
3 (age 40 years; grade 2; pT1c pN1a; ER approximately 50%; PR approximately 50%). (‡) Example of clinical case 4 (age 39 years; grade
3; pT2 pN1a; ER, 95%; PR, 40%). (§) TAILORx provided data for patients with node-negative disease only; results of RxPONDER in
patients with one to three positive nodes are awaited. (||) Low-risk was defined as tumor# 3 cm and grade 1 or tumor# 2 cm and grade 2
or tumor# 1 cm and grade 3 (and when the low-risk criteria were not met, the clinical risk was defined as high). AI, aromatase inhibitor;
CT, chemotherapy; OFS, ovarian function suppression; RS, recurrence score; Tam, tamoxifen.
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quantification of treatment benefit, the Regan risk score (for
which a Web application will be available online soon) has
a major impact on clinical practice by allowing clearer
counseling of the pros and cons of the proposed options; thus,
the Regan risk score may be a valid tool to increase women’s
motivation to follow the prescribed treatment.47 Recent data
from TAILORx also suggest the possibility to better optimize
chemotherapy indications for the cohort of patients with node-
negative disease within the gray zone of the intermediate-risk
category by theRegan risk score.22 Taken together, these data
have allowed another step toward improving adjuvant en-
docrine treatment tailoring for premenopausal patients (Fig 1).
Clinical case 1 reports about a patient who, after breast-
conserving surgery, was diagnosed with a disease that can
be defined as low risk (stage I, lymph node negative, grade
1, estrogen receptor/progesterone receptor strongly posi-
tive, Ki67 low) according to the Regan risk score without the
need for genomic tests to make adjuvant treatment de-
cisions. After multidisciplinary discussion, adjuvant radio-
therapy and endocrine therapy with tamoxifen alone for
5 years was recommended.
Clinical case 2 is in the gray zone of the intermediate-risk
category (stage I, lymph node negative, grade 2, estrogen
receptor/progesterone receptor intermediate expression)
by the Regan risk score, for which the 21-gene assay results
is of added value to optimize disease management; with
a RS of 21, we opted for anthracycline-free chemotherapy
followed by OFS plus tamoxifen after discussion of the
different toxicity profile of the two oral endocrine agents.
However, during patient counseling, the potential over-
treatment with chemotherapy administration and the
possibility that the same benefit expected with adjuvant
treatments could have been obtained by OFS plus an AI
without prior chemotherapy was discussed.
Clinical case 3 falls also within the intermediate-risk category
by the Regan risk score (stage II, one of three sentinel lymph
nodes positive, grade 2, and estrogen receptor/progesterone
receptor intermediate expression); the patient came to our
center after receiving anthracycline-free chemotherapy. She
resumed ovarian function after chemotherapy. We suggested
the use of OFS with tamoxifen or an AI; after discussing the
different toxicity profile of the two oral endocrine agents, the AI
was preferred and started after the second administration of
a GnRHa with estradiol and FSHmonitoring every 3-6months
at least during the first year of treatment.
Clinical case 4 describes a high-risk patient according to
the Regan risk score (stage II, three positive lymph nodes,
grade 3, estrogen receptor strongly positive, progesterone
receptor intermediate expression); without the need for
genomic tests to make adjuvant treatment decisions,
anthracycline- and taxane-based chemotherapy was rec-
ommended. The patient has three children but was con-
cerned about risk of chemotherapy-induced premature
ovarian insufficiency. A GnRHa was started 1 week before
chemotherapy; an AI was added after the end of cytotoxic
therapy with estradiol and FSH monitoring.
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